MDA-MB-157细胞

MDA-MB-157/MDA-MB-157细胞系/MDA-MB-157细胞株/MDA-MB-157人乳腺癌细胞

Cell line name MDA-MB-157

Synonyms MDA-MB157; MDAMB157; MDA-157; MDA157; MB 157; MB157; MD Anderson-Metastatic Breast-157

Accession CVCL_0618

Secondary accession CVCL_3740

Resource Identification Initiative To cite this cell line use: MDA-MB-157 (RRID:CVCL_0618)

Comments Group: Triple negative breast cancer (TNBC) cell line.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: JWGray breast cancer cell line panel.

Part of: ICBP43 breast cancer cell line panel.

Part of: MD Anderson Cell Lines Project.

Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).

Population: African American.

Doubling time: 2.8 days (PubMed=9671407); 66.98 hours (JWGray panel).

Microsatellite instability: Stable (MSS) (PubMed=15677628; Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: Glycoproteome analysis by proteomics.

Omics: miRNA expression profiling.

Omics: Protein expression by reverse-phase protein arrays.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Misspelling: MDA-MB-15; Cosmic=897421.

Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.

Sequence variations

Mutation; HGNC; 7329; MSH6; Simple; p.Pro42Ser (c.124C>T); ClinVar=VCV000089180; Zygosity=Heterozygous (PubMed=19593635; DepMap=ACH-000621).

Mutation; HGNC; 7329; MSH6; Simple; p.Arg644Ser (c.1932G>C); ClinVar=VCV000089233; Zygosity=Heterozygous (PubMed=19593635; DepMap=ACH-000621).

Mutation; HGNC; 11998; TP53; Simple; p.Pro87fs*53 (c.261_286del26) (p.Ala88Cysfs*52); Zygosity=Homozygous (PubMed=16541312; ATCC=HTB-24; DepMap=ACH-000621).

HLA typing Source: PubMed=25960936

Class I

HLA-A A*11:01,68:02

HLA-B B*15:03,55:02

HLA-C C*01:02,02:02

 

Source: PubMed=26589293

Class I

HLA-A A*02:01,30:01

HLA-B B*53:01,53:01

HLA-C C*04:01,06:02

Class II

HLA-DQ DQA1*01:02,03:02

DQB1*06:02,06:02

HLA-DR DRB1*11:09,15:01

Genome ancestry Source: PubMed=30894373

 

Origin % genome

African 77.9

Native American 0

East Asian, North 4.71

East Asian, South 0

South Asian 0

European, North 1.3

European, South 16.09

Disease Breast carcinoma (NCIt: C4872)

Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)

Sex of cell Female

Age at sampling 44Y

Category Cancer cell line

STR profile Source(s): AddexBio=C0006020/4986; ATCC=CRL-7721; ATCC=HTB-24; CCRID=1101HUM-PUMC000077; Cosmic-CLP=925338; ECACC=92020422; PubMed=20679594; PubMed=25877200; PubMed=28889351

 

Markers:

Amelogenin X

CSF1PO 10

D2S1338 25

D3S1358 16

D5S818 12

D7S820 10,11

D8S1179 12,14

D13S317 11 (AddexBio=C0006020/4986; ATCC=CRL-7721; CCRID=1101HUM-PUMC000077; Cosmic-CLP=925338; ECACC=92020422; PubMed=20679594; PubMed=25877200; PubMed=28889351)

11,12 (ATCC=HTB-24)

D16S539 11

D18S51 13,16 (ATCC=CRL-7721; ATCC=HTB-24)

16 (CCRID=1101HUM-PUMC000077; PubMed=25877200)

D19S433 13,14.2 (ATCC=CRL-7721; ATCC=HTB-24)

14.2 (CCRID=1101HUM-PUMC000077)

D21S11 31,31.2

FGA 22,23 (ATCC=CRL-7721)

23 (ATCC=HTB-24; CCRID=1101HUM-PUMC000077; PubMed=25877200)

Penta D 3.2,9

Penta E 11

TH01 7,8

TPOX 9,11 (AddexBio=C0006020/4986; ATCC=CRL-7721; ATCC=HTB-24; ECACC=92020422; PubMed=20679594; PubMed=25877200; PubMed=28889351)

11 (CCRID=1101HUM-PUMC000077; Cosmic-CLP=925338)

vWA 15

 

Run an STR similarity search on this cell line

Web pages

PubMed=4412247; DOI=10.1093/jnci/53.3.661; PMCID=PMC7364228

Cailleau R.M., Young R., Olive M., Reeves W.J. Jr.

Breast tumor cell lines from pleural effusions.

J. Natl. Cancer Inst. 53:661-674(1974)

 

PubMed=4471183; DOI=10.1007/BF02616069

Young R.K., Cailleau R.M., Mackay B., Reeves W.J. Jr.

Establishment of epithelial cell line MDA-MB-157 from metastatic pleural effusion of human breast carcinoma.

In Vitro 9:239-245(1974)

 

PubMed=833871; DOI=10.1093/jnci/58.2.209

Fogh J., Wright W.C., Loveless J.D.

Absence of HeLa cell contamination in 169 cell lines derived from human tumors.

J. Natl. Cancer Inst. 58:209-214(1977)

 

PubMed=730202; DOI=10.1007/BF02616120

Cailleau R.M., Olive M., Cruciger Q.V.J.

Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.

In Vitro 14:911-915(1978)

 

PubMed=3518877; DOI=10.3109/07357908609038260

Fogh J.

Human tumor lines for cancer research.

Cancer Invest. 4:157-184(1986)

 

PubMed=1961733; DOI=10.1073/pnas.88.23.10657; PMCID=PMC52989

Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S.

Mutations in p53 as potential molecular markers for human breast cancer.

Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991)

 

DOI=10.1016/B978-0-12-333530-2.50009-5

Leibovitz A.

Cell lines from human breast.

(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994)

 

PubMed=9671407; DOI=10.1038/sj.onc.1201814

Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.

Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.

Oncogene 16:2865-2878(1998)

 

PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B

Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J.J., Larsson C.

Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.

Genes Chromosomes Cancer 28:308-317(2000)

 

PubMed=10969801

Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.

Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.

Cancer Res. 60:4519-4525(2000)

 

PubMed=11044355; DOI=10.1054/bjoc.2000.1458; PMCID=PMC2408781

Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C., Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.

Molecular cytogenetic analysis of breast cancer cell lines.

Br. J. Cancer 83:1309-1317(2000)

 

PubMed=11343771; DOI=10.1016/S0165-4608(00)00387-3

Rummukainen J., Kytola S., Karhu R., Farnebo F., Larsson C., Isola J.J.

Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.

Cancer Genet. Cytogenet. 126:1-7(2001)

 

PubMed=12353263; DOI=10.1002/gcc.10107

Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M.

Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.

Genes Chromosomes Cancer 35:204-218(2002)

 

PubMed=12800145; DOI=10.1002/gcc.10218

Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.

A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.

Genes Chromosomes Cancer 37:333-345(2003)

 

PubMed=15153330; DOI=10.1593/neo.3292; PMCID=PMC1502105

Watts G.S., Oshiro M.M., Junk D.J., Wozniak R.J., Watterson S.J., Domann F.E., Futscher B.W.

The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells.

Neoplasia 6:187-194(2004)

 

PubMed=15677628; DOI=10.1093/carcin/bgi032

Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.

Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.

Carcinogenesis 26:923-930(2005)

 

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853

Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.

BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

Cancer Res. 66:41-45(2006)